38.73
+0.24(+0.62%)
Currency In USD
| Previous Close | 38.49 |
| Open | 38.45 |
| Day High | 39.15 |
| Day Low | 37.88 |
| 52-Week High | 53.27 |
| 52-Week Low | 29.24 |
| Volume | 333,934 |
| Average Volume | 483,763 |
| Market Cap | 2.51B |
| PE | -16.55 |
| EPS | -2.34 |
| Moving Average 50 Days | 42.38 |
| Moving Average 200 Days | 41.6 |
| Change | 0.24 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $1,164.46 as of February 05, 2025 at a share price of $38.73. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 3 years ago, it would be worth $943.25 as of February 05, 2025 at a share price of $38.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
GlobeNewswire Inc.
Jan 30, 2025 12:00 PM GMT
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
GlobeNewswire Inc.
Jan 14, 2025 12:00 PM GMT
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and plans to initiate parallel Phase 2b trials in AD and
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
GlobeNewswire Inc.
Jan 07, 2025 12:00 PM GMT
WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological